NAT10 directly interacts with PARP1, promoting the acetylation of PARP1 transcripts, conferring resistance to platinum‐based drugs, regulating the breast cancer EMT process, and promoting doxorubicin resistance.135. Here, PARP1 is linked to breast cancer.